The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs

  title={The Role of Pharmacokinetics and Pharmacodynamics in the Development of Biotech Drugs},
  author={Bernd Meibohm},

Figures from this paper

Integrating cell-level kinetic modeling into the optimization of cancer therapeutics
A detailed mechanistic model of the targeted cellular system that explicitly takes into account receptor binding and trafficking inside the cell is presented and that is used to derive reduced models of drug degradation which retain a mechanistic interpretation. Expand
Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies
Although the exact mechanism of drug transport from the nose to the brain is not fully understood and its effectiveness in humans is unclear, it appears that the intranasal route together with the use of NLCs, SLNs or NEs is advantageous for targeting drugs to thebrain. Expand
Safety and efficacy of interleukin inhibitors in elderly patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis
The reviewed findings suggest that the interleukin inhibitors approved and currently in use in clinical practice for the treatment of rheumatoid arthritis, psoriasis, and psoriatic arthritis can be considered a safe and efficient option for these diseases in elderly patients. Expand
Challenges in the Pharmacokinetics of Therapeutic Proteins
Analysis of pharmacokinetic similarity of biologics using nonlinear mixed effects modelling
Our objective was to show with two examples that a pharmacokinetic (PK) similarity analysis can be performed with nonlinear mixed effects models (NLMEM). We used two studies comparing differentExpand
Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.
This review article will focus on the current use of mass spectrometry for the study of the metabolism of peptide and protein drugs. Expand
Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed‐Effects Modeling
It is shown that a pharmacokinetic (PK) similarity analysis can be performed using nonlinear mixed‐effects models (NLMEM) because NCA is an easier approach because it does not require data modeling; however, NLMEM leads to a better understanding of the underlying biological system. Expand
Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling
A systematic approach to integrate cell-level kinetic models and pharmacokinetic compartment models for the development of therapeutic antibodies indicates that observed differences in the therapeutic effects of high affinity antibodies in the market and in clinical development may result mainly from Fc-mediated indirect mechanisms such as antibody-dependent cell cytotoxicity. Expand


Betting on biogenerics
Although patent expiry might normally signal an influx of generic competition, there are a number of hurdles to overcome before biogenerics can be successfully commercialized. Expand
Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives
Pharmacokinetic/pharmacodynamic (PK/PD)-modeling links dose-concentration relationships (PK) and concentration-effect relationships (PD), thereby facilitating the description and prediction of theExpand
Mono - clonal antibodies market
  • ICH E 4 – Dose - Response Information to Support Drug Registration . European Agency for the Evaluation of Medicinal Products , London . 22 International Conference on Harmonization . 1997 . ICH S 6 – Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals
  • 2004
Pharmacokinetic aspects of biotechnology products.
Extensive use of pharmacokinetic and exposure/response concepts in all phases of drug development has in the past been identified as a crucial factor for the success of a scientifically driven, evidence-based, and thus accelerated drug development process. Expand
Pharmacokinetic/Pharmacodynamic Modeling in Drug Development
Pharmacokinetic (PK) and pharmacodynamic (PD) modeling is employed to establish correlation of the concentration-time relationship (PK) with effect-concentration relationship (PD) in order to provideExpand
The further evolution of biotech
Born 20 years ago with the launch of recombinant insulin, the biotechnology industry is maturing, with several leading companies now rivalling traditional pharmaceutical companies in many ways. WhatExpand
Pharma 2010: The Threshold to Innovation
  • IBM Business Consulting Services,
  • 2002
Pharmacokinetic/pharmacodynamic studies in drug product development.
Rigorous implementation of the PK/PD concepts in drug product development provides a rationale, scientifically based framework for efficient decision making regarding the selection of potential drug candidates, for maximum information gain from the performed experiments and studies, and for conducting fewer, more focused clinical trials with improved efficiency and cost effectiveness. Expand
The evolution of biotech
Abstract Twenty years ago, the commercial launch of recombinant insulin, the first biotechnology-derived drug, marked the birth of biotech. Today, biotech is coming into its own as a matureExpand
Faster Drug Development
  • Appl . Clin . Trials
  • 2000